JP2005511722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511722A5 JP2005511722A5 JP2003550791A JP2003550791A JP2005511722A5 JP 2005511722 A5 JP2005511722 A5 JP 2005511722A5 JP 2003550791 A JP2003550791 A JP 2003550791A JP 2003550791 A JP2003550791 A JP 2003550791A JP 2005511722 A5 JP2005511722 A5 JP 2005511722A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- composition according
- active ingredient
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 8
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 238000007887 coronary angioplasty Methods 0.000 claims 2
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33924901P | 2001-12-11 | 2001-12-11 | |
| US60/339,249 | 2001-12-11 | ||
| PCT/US2002/039289 WO2003049742A1 (en) | 2001-12-11 | 2002-12-06 | Method for administering birb 796 bs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511722A JP2005511722A (ja) | 2005-04-28 |
| JP2005511722A6 JP2005511722A6 (ja) | 2005-08-04 |
| JP2005511722A5 true JP2005511722A5 (https=) | 2006-02-02 |
Family
ID=23328156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550791A Pending JP2005511722A (ja) | 2001-12-11 | 2002-12-06 | Ｂｉｒｂ７９６ｂｓの投与方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20030118575A1 (https=) |
| EP (1) | EP1455791A1 (https=) |
| JP (1) | JP2005511722A (https=) |
| AU (1) | AU2002366644A1 (https=) |
| CA (1) | CA2465759A1 (https=) |
| WO (1) | WO2003049742A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110755A1 (en) * | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| FR2846328B1 (fr) * | 2002-10-23 | 2004-12-10 | Servier Lab | Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CA2536293A1 (en) * | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating copd and pulmonary hypertension |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| EP1824843A2 (en) | 2004-12-07 | 2007-08-29 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| JP2008523071A (ja) | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ， インコーポレイテッド | Ｍａｐキナーゼの尿素インヒビター |
| US8096882B2 (en) * | 2005-02-04 | 2012-01-17 | The Invention Science Fund I, Llc | Risk mitigation in a virtual world |
| US7774275B2 (en) * | 2005-02-28 | 2010-08-10 | Searete Llc | Payment options for virtual credit |
| US8473382B2 (en) * | 2006-02-28 | 2013-06-25 | The Invention Science Fund I, Llc | Virtual collateral for real-world obligations |
| US20070156509A1 (en) * | 2005-02-04 | 2007-07-05 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Real-world incentives offered to virtual world participants |
| US8271365B2 (en) * | 2005-02-04 | 2012-09-18 | The Invention Science Fund I, Llc | Real-world profile data for making virtual world contacts |
| US20080103951A1 (en) * | 2005-02-04 | 2008-05-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual credit in simulated environments |
| US20090138333A1 (en) * | 2005-02-04 | 2009-05-28 | Searete Llc, A Limited Liablity Of The State Of Delaware | Follow-up contacts with virtual world participants |
| US7937314B2 (en) * | 2005-10-21 | 2011-05-03 | The Invention Science Fund I | Disposition of component virtual property rights |
| US8556723B2 (en) * | 2005-02-04 | 2013-10-15 | The Invention Science Fund I. LLC | Third party control over virtual world characters |
| US20080092065A1 (en) * | 2005-02-04 | 2008-04-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Third party control over virtual world characters |
| US20070168214A1 (en) * | 2005-03-30 | 2007-07-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual credit with transferability |
| US20070118420A1 (en) * | 2005-02-04 | 2007-05-24 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Context determinants in virtual world environment |
| US20080215434A1 (en) * | 2005-02-04 | 2008-09-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Real world interaction with virtual world privileges |
| US7958047B2 (en) | 2005-02-04 | 2011-06-07 | The Invention Science Fund I | Virtual credit in simulated environments |
| US8457991B2 (en) * | 2005-02-04 | 2013-06-04 | The Invention Science Fund I, Llc | Virtual credit in simulated environments |
| US20090043683A1 (en) * | 2005-02-04 | 2009-02-12 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual world reversion rights |
| US20090144148A1 (en) * | 2005-02-04 | 2009-06-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Attribute enhancement in virtual world environments |
| US20070198305A1 (en) * | 2005-03-30 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual credit with transferability |
| US7720687B2 (en) | 2005-10-03 | 2010-05-18 | The Invention Science Fund I, Llc | Virtual world property disposition after real-world occurrence |
| US20090099930A1 (en) * | 2005-02-04 | 2009-04-16 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Participation profiles of virtual world players |
| US20080270165A1 (en) * | 2005-02-04 | 2008-10-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual world property disposition after real-world occurrence |
| US7890419B2 (en) * | 2005-02-04 | 2011-02-15 | The Invention Science Fund I, Llc | Virtual credit in simulated environments |
| US8512143B2 (en) * | 2005-07-18 | 2013-08-20 | The Invention Science Fund I, Llc | Third party control over virtual world characters |
| US8060829B2 (en) | 2005-04-15 | 2011-11-15 | The Invention Science Fund I, Llc | Participation profiles of virtual world players |
| US8566111B2 (en) * | 2005-02-04 | 2013-10-22 | The Invention Science Fund I, Llc | Disposition of component virtual property rights |
| US20070013691A1 (en) * | 2005-07-18 | 2007-01-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Supervisory authority in virtual world environment |
| US20070078737A1 (en) * | 2005-02-28 | 2007-04-05 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Financial ventures based on virtual credit |
| US20100016449A1 (en) * | 2006-12-21 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Formulations with Improved Bioavailability |
| EP3257862A1 (en) | 2016-06-16 | 2017-12-20 | ETH Zürich | Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4105766A (en) * | 1977-08-19 | 1978-08-08 | Sterling Drug Inc. | 4,5-Dihydro-5-oxopyrazolo[1,5-a]quinazoline-3-carboxylic acid derivatives |
| HU185294B (en) * | 1980-12-29 | 1984-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing substituted urea derivatives |
| US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
| MX9300141A (es) * | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| US5869043A (en) * | 1993-09-17 | 1999-02-09 | Smithkline Beecham Corporation | Drug binding protein |
| PT724588E (pt) * | 1993-09-17 | 2000-05-31 | Smithkline Beecham Corp | Proteina de ligacao a farmacos |
| US5783664A (en) * | 1993-09-17 | 1998-07-21 | Smithkline Beecham Corporation | Cytokine suppressive anit-inflammatory drug binding proteins |
| US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
| US5948885A (en) * | 1996-05-20 | 1999-09-07 | Signal Pharmaceuticals, Inc. | Mitogen-activated protein kinase p38-2 and methods of use therefor |
| EP0906307B1 (en) * | 1996-06-10 | 2005-04-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| US5851812A (en) * | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| MXPA01008440A (es) * | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
| US6565880B2 (en) * | 2000-07-24 | 2003-05-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| CA2454913A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
| EP1438048A1 (en) * | 2001-10-18 | 2004-07-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
-
2002
- 2002-12-06 EP EP02804546A patent/EP1455791A1/en not_active Withdrawn
- 2002-12-06 US US10/313,667 patent/US20030118575A1/en not_active Abandoned
- 2002-12-06 JP JP2003550791A patent/JP2005511722A/ja active Pending
- 2002-12-06 CA CA002465759A patent/CA2465759A1/en not_active Abandoned
- 2002-12-06 AU AU2002366644A patent/AU2002366644A1/en not_active Abandoned
- 2002-12-06 WO PCT/US2002/039289 patent/WO2003049742A1/en not_active Ceased
-
2007
- 2007-05-01 US US11/742,975 patent/US20070203141A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511722A5 (https=) | ||
| JP2005523338A5 (https=) | ||
| JP2005529890A5 (https=) | ||
| ES2251360T3 (es) | Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios. | |
| JP2002539206A5 (https=) | ||
| NZ591115A (en) | Azaindazole compounds as ccr1 receptor antagonists | |
| JP2010535218A5 (https=) | ||
| JP2006514950A5 (https=) | ||
| JP2009531292A5 (https=) | ||
| JP2004531571A5 (https=) | ||
| JP2023106403A5 (https=) | ||
| SG10201900535UA (en) | Novel anti-il 13 antibodies and uses thereof | |
| EP2079732A1 (en) | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist | |
| JP2012525346A5 (https=) | ||
| JP2009537596A (ja) | ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用 | |
| JP2006504667A5 (https=) | ||
| RU2007102576A (ru) | Новые индаэолкарбоксамиды и их применение | |
| JP2018502579A5 (https=) | ||
| JP2021113239A5 (https=) | ||
| JP2010537994A5 (https=) | ||
| NZ547523A (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
| JP2014511897A5 (https=) | ||
| HRP20200001T1 (hr) | Kristalični oblik spoja (s)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol | |
| JP2005527570A5 (https=) | ||
| SG137859A1 (en) | Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same |